Skip to content
printicon
Main menu hidden.

Cancer research - PI Hemmingsson

Research project

Clinical and experimental studies of cancer. We are running a randomized clinical trial on local treatment of breast cancer liver metastases and participate in several trials in national and international collaborations. In our lab, we study the MAPK signaling pathway and develop a model i C. elegans to identify novel treatments of cancer.

Head of project

Oskar Hemmingsson
Associate professor, senior consultant (attending) physician, other position
E-mail
Email

Project overview

Project period:

Start date: 2013-01-01

Funding

Our group has funding from:

  • Wenner-Gren Foundations
  • the Swedish Society of Medicine
  • the Cancer research fund in northern Sweden
  • the County Council (ALF-means)
  • the Wallenberg Center for Molecular Medicine.
  • Swedish Breast Cancer Association
  • The Swedish Research Council

Participating departments and units at Umeå University

Department of Surgical and Perioperative Sciences

Research area

Cancer, Clinical medicine

Project description

Clinical studies

We are running the multicenter randomized clinical trial BRECLIM to study if local treatment should be offered to patients suffering from breast cancer liver metatsases. Read more here. 

We participate in the EPIC-network to study hepatocellular cancer and melanoma. We also participate in the international snapshot study of outcomes after liver surgery and in studies within the national registry on cancer in the liver and the bile ducts 

In addition we recruit participants to the clinical studies, ASAC  , NorPACT  and Keynote-937.

Experimental studies

Cancer progression is often driven by oncogenic mutations in the MAPK signalling pathway. Our group studies BRAF- and KRAS-activated cancer to explore targets to circumvent drug resistance and to find novel treatments. Currently, we focus on the tumour suppressor LRIG1 in relation to BRAF inhibitor resistance in malignant melanoma. We take advantage of the biobanks in Umeå in order to confirm results from in vitro cell culture studies in a patient material. Our group has experience from the model organism C. elegans and we recently equipped our lab for nematode research. We develop the C. elegans in vivo model to explore novel targets to block MAPK-driven cancer. https://www.umu.se/en/wallenberg-centre-for-molecular-medicine/research/wcmm-associerade-forskare/oskar-hemmingsson/

In a second project we test a novel concept of surface microdialysis to evaluate perioperative liver metabolism.